Context Therapeutics Stock (NASDAQ:CNTX)

Forecast Ownership Financials Chart

Previous Close

$0.84

52W Range

$0.49 - $2.75

50D Avg

$0.68

200D Avg

$1.06

Market Cap

$76.25M

Avg Vol (3M)

$227.47K

Beta

1.88

Div Yield

CNTX Company Profile

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Oct 20, 2021

Website

CNTX Performance

CNTX Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-29.92M	$-25.07M	$-15.38M
Net Income	$-26.73M	$-23.96M	$-14.29M
EBITDA	$-29.92M	$-25.06M	$-14.83M
Basic EPS	$-0.46	$-1.50	$-0.90
Diluted EPS	$-0.46	$-1.50	$-0.90

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
BFRI	Biofrontera Inc.
TCRX	TScan Therapeutics, Inc.
BOLT	Bolt Biotherapeutics, Inc.
DAWN	Day One Biopharmaceuticals, Inc.
LYRA	Lyra Therapeutics, Inc.
ENSC	Ensysce Biosciences, Inc.
DATS	DatChat, Inc.
PTPI	Petros Pharmaceuticals, Inc.